Patents Assigned to Pharmacia & Upjohn Company
  • Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
    Patent number: 7354724
    Abstract: The present invention provides a Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of homologs in other animals, and of DmGPCR agonists/antagonists, useful for the treatment of diseases in animals and for the control of insects that are injurious or harmful to plants or animals.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: April 8, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Valdin G. Smith, Teresa M. Kubiak, Martha J. Larsen
  • Substituted ureas and carbamates
    Patent number: 7351738
    Abstract: The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 1, 2008
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Shon R. Pulley, John A. Tucker
  • Method of treating chronic fatigue syndrome
    Patent number: 7338953
    Abstract: Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: March 4, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson
  • 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines
    Patent number: 7338965
    Abstract: The invention relates to substituted piperidine, piperazine, morpholine and thiomorpholine compounds useful in the treatment of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major component of the amyloid plaques found in the brains of Alzheimer's sufferers. One embodiment of the invention relates to compounds having the structure: where Z is CR or N, and R1, R2 and R3 are as described in the specification.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: March 4, 2008
    Assignees: Pharmacia & Upjohn Company, Elan Pharmaceuticals, Inc.
    Inventors: Joseph B. Moon, Shon R. Pulley, Daniel H. Rich, David L. Brown, Barbara Jagodzinska, Varghese John, John Jacobs
  • Infection-resistant medical devices
    Patent number: 7322965
    Abstract: A method for preventing medical device-associated microorganism infection includes the steps of providing a medical device and incorporating an effective amount of an oxazolidinone compound, such as linezolid, into the medical device.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: January 29, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: John Kenneth Gibson, Charles W. Ford, Paul J. Pagano
  • Substituted hydroxyethylamines
    Patent number: 7312360
    Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, RN, and Rc are defined herein. These compounds interact with and inhibit the activity of the enzyme beta-secretase. These compounds are therefore useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions and methods of treatment of these diseases are also disclosed.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: December 25, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Ruth TenBrink, Michel Maillard, Martha Warpehoski
  • Transgenic mice knockouts of BACE-1
    Patent number: 7309811
    Abstract: The invention provides transgenic animals that are heterozygous or homozygous for a nonfunctional allele of BACE-1. These animals show normal development indicating that BACE-1 is not necessary for development and hence is an appropriate therapeutic target. The transgenic animals are useful in various screening assays including identifying inhibitors of other enzymes involved in processing of APP to A? and determining a toxicity profile of inhibitors of BACE-1.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 18, 2007
    Assignees: Elan Pharmaceuticals, Inc, Pharmacia & Upjohn Company
    Inventors: Lisa McConlogue, Mark E. Gurney
  • Therapeutic compounds
    Patent number: 7291738
    Abstract: The present invention provides compounds, for example, of formula (I): wherein R1, R2, and R3 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods, and processes and intermediates useful for preparing compounds of formula I.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: November 6, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jian-Min Fu
  • Method of treating chronic fatigue syndrome
    Patent number: 7276503
    Abstract: Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: October 2, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
    Publication number: 20070225374
    Abstract: The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: November 1, 2004
    Publication date: September 27, 2007
    Applicants: ELAN PHARMACEUTICALS, INC., PHARMACIA & UPJOHN COMPANY LLC
    Inventor: John Tucker
  • Hydroxypropyl amides for the treatment of Alzheimer's disease
    Patent number: 7262208
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: August 28, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: John A. Tucker, Brian A. Sherer, Ying Zi Xu, Louis Brogley, Shon R. Pulley, Jon S. Jacobs, James P. Beck, Varghese John
  • 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors
    Patent number: 7256189
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 14, 2007
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Salts and polymorphs of a pyrrole-substituted indolinone compound
    Patent number: 7247627
    Abstract: The invention relates to non-hygroscopic salts of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, such as maleate salts, and to crystalline polymorphs of these salts. The invention further relates to pharmaceutical compositions of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide salts, and methods of treating disorders such as cancer using such compositions.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: July 24, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Andrei Blasko, Qingwu Jin, Qun Lu, Michael A. Mauragis, Dian Song, Brenda S. Vonderwell
  • Double mutant alpha-7 nicotinic acetylcholine receptors
    Patent number: 7247706
    Abstract: The invention relates ton novel methods for measuring ion channel transmission and methods and compositions useful in the indentification of ligand gated channel agonists and modulators.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: July 24, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Vincent E. Groppi, Jr., Mitchell B. Berkenpas
  • Hydroxypropylamines
    Patent number: 7244755
    Abstract: Disclosed are compounds of formula I: and the pharmaceutically acceptable salts thereof wherein the variables RN, R1, R2, R3, RP and RC are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: July 17, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jed F. Fisher, Jon S. Jacobs, Brian Sherer
  • Acetyl 2-hydroxy-1, 3-diaminoalkanes
    Patent number: 7244725
    Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and RC are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: July 17, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth TenBrink
  • Method of treating peripheral neuropathy
    Patent number: 7241762
    Abstract: Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: July 10, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • NEW TREATMENTS FOR NERVOUS DISORDERS
    Publication number: 20070149527
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: February 15, 2007
    Publication date: June 28, 2007
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Fred Hassan, John McCall, Duncan Taylor, Philip Von Voigtlander, Erik Ho Fong Wong
  • Processes to prepare eplerenone
    Patent number: 7235655
    Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: June 26, 2007
  • Compounds and methods for preparing methanesulfonamides
    Patent number: 7232930
    Abstract: A process for preparing (S)-(?)-N-[4-[4-[ethyl(6-fluoro-6-methylheptyl)amino]-1-hydroxy]phenyl]methanesulfonamide hemifumarate salt, which comprises reacting N-[4-[(2S)-tetrahydro-5-hydroxy-2-furanyl]phenyl]methanesulfonamide(IIa) with fluoroamine (III) in the presence of triacetoxyborohydride and ethyl acetate to provide [4-[-4-[ethyl(6-fluoro-6-methylheptyl)amino]-1-hydroxylphenyl]methanesulfonamide (I) and then converting I into the hemifumarate salt Ia. A process for preparing IIa is also claimed as well as intermediates IIa-IId.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: June 19, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Sonja Suzanne MacKey, Michael E. Matison, Haifeng Wu, Michael Paul Goble, Moses W. McMillan, Vikram Gurudath Kalthod